Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753871 | 0.93 | RELA (0.58) | CA1CA2CA12CA14CA7 | |
| SCHEMBL7688181 | 0.91 | RELA (0.61) | CA1CA2CA12CA14CA7 | |
| SCHEMBL28469962 | 0.91 | RELA (0.61) | CA1CA2CA12CA14CA7 | |
| SCHEMBL7042054 | 0.90 | RELA (0.55) | CA1CA2CA12CA14CA7 | |
| SCHEMBL7039396 | 0.90 | RELA (0.55) | CA1CA2CA12CA14CA7 | |
| SCHEMBL608990 | 0.90 | CA1 (0.61) | CA1CA2CA12CA14CA7 | |
| SCHEMBL7109328 | 0.90 | RELA (0.55) | CA1CA2CA12CA14CA7 | |
| SCHEMBL11754427 | 0.89 | RELA (0.59) | CA1CA2CA12CA14CA7 | |
| SCHEMBL7687766 | 0.86 | RELA (0.66) | CA1CA2CA12CA14CA7 | |
| SCHEMBL8679104 | 0.84 | CA1 (0.67) | CA1CA2CA12CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210299257-A1 | Methods, Systems and Apparatus for Reducing Pathogen Loads in Circulating Body Fluids | Mi2 Holdings LLC (US) | 2021-09-30 | — | — | US | disclosed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | disclosed |
| US-9346808-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-24 | — | — | US | disclosed |
| EP-1654324-B1 | SULPHONAMIDE ANIONS AS CATALYSTS FOR NCO OLIGOMERISATION | BAYER MATERIALSCIENCE AG (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-7060817-B2 | Sulfonamide anions as catalysts for NCO oligomerization | BAYER MATERIALSCIENCE AG (DE) | 2006-06-13 | — | — | US | disclosed |
| EP-1654324-A1 | SULPHONAMIDE ANIONS AS CATALYSTS FOR NCO OLIGOMERISATION | Bayer MaterialScience AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005017037-A1 | SULPHONAMIDE ANIONS AS CATALYSTS FOR NCO OLIGOMERISATION | BAYER MATERIALSCIENCE AG (DE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050033005-A1 | Sulfonamide anions as catalysts for NCO oligomerization | BAYER MATERIALSCIENCE AG (DE) | 2005-02-10 | — | — | US | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | CA1 1994/4885CA2 1812/4885CA12 2719/4885 |
| US-20210299257-A1 | Methods, Systems and Apparatus for Reducing Pathogen Loads in Circulating Body Fluids | CD47, CASP10, ROS1 | CA1 1414/4885CA2 1427/4885CA12 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.